Amae Health has secured a $25 million Series B financing to expand its national clinic footprint, further develop its AI-enabled precision care platform, and strengthen partnerships with leading academic medical centers. The round was led by Altos Ventures with participation from existing investors, including Quiet Capital, Bling Capital, Cedars-Sinai Ventures, Healthier Capital, and 8VC, bringing the company’s total funding to more than $50 million. The company, a Public Benefit Corporation, focuses on treating severe mental illnesses such as schizophrenia, bipolar disorder, and treatment-resistant depression through an integrated in-person care model supported by advanced technology.
The new capital will support the opening of additional Amae clinics nationwide. Since establishing its first clinic in Los Angeles in 2022, the company has worked alongside major health systems, including NewYork-Presbyterian, Cedars-Sinai, and Stanford Health Care. Amae’s clinics are staffed by multidisciplinary care teams that deliver coordinated psychiatric, therapeutic, primary care, nutritional, and social services.
The company’s clinical outcomes have shown significant improvements. Amae reports a 30-day hospital readmission rate of less than 4 percent, compared with the national average of 23 percent. Measurement-based care scores have demonstrated improvement across key symptom categories, including mania, psychosis, and suicidality. Every patient transitioning from hospitalization has been able to receive follow-up care within seven to thirty days due to Amae’s same-day intake model. The company also reports a Net Promoter Score of 90, reflecting positive patient experience and satisfaction.
Amae’s care model integrates face-to-face treatment with an AI-powered platform built on Palantir Foundry. This system consolidates patient data from clinical assessments, wearable devices, and medical histories into a real-time view that supports informed clinical decision-making. New technology features include a longitudinal patient dashboard, an AI-enabled assistant that identifies shifts in patient status and suggests treatment pathways, and a system for digital symptom phenotype grouping that helps clinicians tailor individualized care strategies.
To support research and progress toward long-term remission, Amae has launched the Amae Institute, which collaborates with academic medical centers and research hospitals to develop and validate emerging therapeutic approaches.
KEY QUOTES
“Severe mental illness devastates families and communities, yet traditional treatment models haven’t moved the needle. We’re taking a different path; combining compassionate, in-person care with responsibly deployed AI that helps clinicians determine the best course for each individual. Our north star is a true cure, defined as it is in oncology: five or more years of remission.”
Stas Sokolin, Co-Founder and CEO, Amae Health
“Amae is advancing a model of care that prioritizes clinical excellence and compassionate, patient-centered services. By combining an outstanding team of clinicians with a thoughtful approach to long-term care, Amae is delivering outcomes that are both significant and sustainable.”
Dr. Itai Danovitch, Chair of the Department of Psychiatry and Behavioral Neurosciences, Cedars-Sinai Medical Center
